Lv3
344 积分 2025-05-28 加入
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China
1天前
已完结
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
5天前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
5天前
已完结
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
5天前
已完结
Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting
6天前
已完结
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
12天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
12天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
12天前
已完结
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs
12天前
已完结
Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy
19天前
已完结
皖公网安备34019202002308
